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Summary Background Data: The epidemiology of venous throm-
boembolism (VTE) after cancer surgery is based on clinical trials on
VTE prophylaxis that used venography to screen deep vein throm-
bosis (DVT). However, the clinical relevance of asymptomatic
venography-detected DVT is unclear, and the population of these
clinical trials is not necessarily representative of the overall cancer
surgery population.
Objective: The aim of this study was to evaluate the incidence of
clinically overt VTE in a wide spectrum of consecutive patients
undergoing surgery for cancer and to identify risk factors for VTE.
Methods: @RISTOS was a prospective observational study in
patients undergoing general, urologic, or gynecologic surgery. Pa-
tients were assessed for clinically overt VTE occurring up to 30 
5 days after surgery or more if the hospital stay was longer than 35
days. All outcome events were evaluated by an independent Adju-
dication Committee.
Results: A total of 2373 patients were included in the study: 1238
(52%) undergoing general, 685 (29%) urologic, and 450 (19%)
gynecologic surgery. In-hospital prophylaxis was given in 81.6%
and postdischarge prophylaxis in 30.7% of the patients. Fifty pa-
tients (2.1%) were adjudicated as affected by clinically overt VTE
(DVT, 0.42%; nonfatal pulmonary embolism, 0.88%; death 0.80%).
The incidence of VTE was 2.83% in general surgery, 2.0% in
gynecologic surgery, and 0.87% in urologic surgery. Forty percent
of the events occurred later than 21 days from surgery. The overall
death rate was 1.72%; in 46.3% of the cases, death was caused by
VTE. In a multivariable analysis, 5 risk factors were identified: age
above 60 years (2.63, 95% confidence interval, 1.21–5.71), previous
VTE (5.98, 2.13–16.80), advanced cancer (2.68, 1.37–5.24), anes-
thesia lasting more than 2 hours (4.50, 1.06–19.04), and bed rest
longer than 3 days (4.37, 2.45–7.78).
Conclusions: VTE remains a common complication of cancer
surgery, with a remarkable proportion of events occurring late after
surgery. In patients undergoing cancer surgery, VTE is the most
common cause of death at 30 days after surgery.
(Ann Surg 2006;243: 89–95)
Venous thromboembolism (VTE) is a common complica-tion in patients undergoing surgery.1,2 Cancer surgery
seems to have at least twice the risk of postoperative deep
vein thrombosis (DVT) and more than 3 times the risk of fatal
pulmonary embolism (PE) than similar procedures in non-
cancer patients.3–5
The epidemiology of VTE after cancer surgery is es-
sentially based on the findings of intervention clinical trials
on VTE prophylaxis that used venography to detect DVT.6
However, the clinical relevance of asymptomatic venogra-
phy-detected DVT is unclear,7 and patients included in these
clinical trials are not necessarily representative of the overall
cancer surgery population since in these studies strict inclu-
sion and exclusion criteria are generally used.
Current epidemiology of VTE after cancer surgery is
mainly based on studies performed over 20 years ago.5 The
risk for thromboembolic complications in cancer surgery may
have altered over the years as this particular surgery has
witnessed a number of recent changes. On one hand, im-
provements in surgical techniques, more prompt mobiliza-
tion, improved use of prophylaxis, and advances in periop-
erative care may have reduced the risk for VTE. On the other
hand, more extensive procedures in older and sicker patients
and preoperative chemotherapy and/or radiotherapy may
have increased the risk of VTE in patients undergoing cancer
surgery nowadays. Furthermore, shorter hospital stays for
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surgery plus extended duration of prophylaxis could influence
the time course of the occurrence of thromboembolic events
today. Finally, most of the available data have been obtained
from studies that limited their observation to the first 7 to 10
postoperative days,5 while few data have been reported on the
incidence of clinically overt events over longer periods.8
All these elements highlight the need for up-to-date
data on the epidemiology of VTE following cancer surgery.
The aim of this study was to prospectively evaluate the
incidence of clinically overt VTE in a wide spectrum of
consecutive patients undergoing cancer surgery and to iden-
tify potential risk factors for VTE. Patients were assessed for
clinically overt VTE occurring up to 30  5 days from
surgery or more in the case of longer hospital stays.
MATERIALS AND METHODS
@RISTOS was a prospective registry performed in 31
Italian surgery departments with a high rate of cancer oper-
ations. Data were collected from consecutive patients under-
going abdominal, thoracic, gynecologic, and urologic surgery
for cancer. Both curative and palliative, nonendoscopic or
endoscopic interventions, interventions on primary tumor(s)
and/or secondary lesion(s) were included.
The aim of the study was to assess the incidence of
clinically overt VTE (DVT, PE, death due to PE) in cancer
patients during a period of 30  5 days from surgery or more
if hospital stay was longer than 35 days, and to identify
potential risk factors for VTE.
At hospital admission information on patients’ charac-
teristics (medical history for possible risk factors for VTE and
concomitant diseases) and presurgery anticancer treatments
were collected. At discharge, relevant data were recorded
concerning surgery, antithrombotic prophylaxis, postsurgery
anticancer treatments, bleeding complications, and venous
thromboembolic events. At 30  5 days from surgery, infor-
mation on antithrombotic prophylaxis, adjuvant chemotherapy/
radiotherapy, bleeding complications, and venous thrombo-
embolic events were collected.
The registry did not issue diagnostic algorithms or
guidelines for management of patients included in the study.
Patients were instructed to report to the study center if symp-
toms developed that were suggestive of VTE or bleeding.
All clinically suspected venous thromboembolic events
and all cases of death were reviewed by an external indepen-
dent Adjudication Committee composed of 3 clinicians. Two
reviewed independently the patients’ clinical documents
(hospital chart, imaging examinations such as ultrasonogra-
phy, venography, perfusion lung scan, CT scan, and autopsy
findings, if available). In the case of divergent interpretation,
the patients’ records were reviewed by the third member.
The study was approved by the Ethic Committees of all
participating centers. Informed consent for handling of per-
sonal data was obtained from all patients. Data collection and
management were performed by using a Web-based system
(Hypernet, Hyperphar Group, Milan, Italy, with CINECA
technology, Bologna, Italy), allowing real-time control of
collected data. A minimum of 3 monitoring visits was per-
formed in each center to verify the consistency between
source documents and data reported on the electronic case
report forms.
Statistical Analysis
A sample size of 2000 patients was considered appro-
priate to document a reliable estimate of the incidence of
clinically overt VTE with sufficiently narrow confidence
intervals of the estimate, by hypothesizing an incidence
between 2% and 5%.
Summary statistics were calculated for all patient vari-
ables. For continuous variables, mean, standard deviation (SD),
median, minimum, and maximum values were assessed.
Statistical analysis was carried out using SAS version.
8.2. Data analysis was carried out according to a pre-estab-
lished plan. The association with the study outcomes of
prognostic factors, such as age, prior DVT or PE, tumor
stage, duration of anesthesia, duration of bed rest, was eval-
uated by a multivariable logistic regression. Covariates for
logistic regression analysis were selected on the basis of their
clinical plausibility and following the general rule of thumb,
which states that the ratio between the overall number of
events and the number of explanatory variables should be at
least equal to 10. An additional multivariable logistic regres-
sion analysis was performed to relate the use or not of
antithrombotic prophylaxis with some covariates (age, tumor
staging, type and duration of anesthesia, endoscopic or non-
endoscopic surgery, intervention on primary tumor(s) and/or
secondary lesion(s)).
Odds ratios (ORs) and 95% confidence intervals (CI)
were reported with 2-tailed probability values. A P value0.05
was considered statistically significant.
RESULTS
Study Population and Surgery
A total of 2373 patients were included in the study.
Male patients were 1283 (54.1%); the mean age of study
population was 63.6 years (SD, 12.4 years). A history of VTE
was reported by 41 (1.7%) patients. A total of 107 patients
(4.5%) underwent preoperative chemotherapy and/or radio-
therapy. Major surgery had been performed in 2.8% of
patients in the 3 months before inclusion in the study.
A total of 1238 patients (52.2%) underwent general
surgery (49.1% abdominal and 3.1% thoracic surgery), and
450 (18.9%) and 685 (28.8%) patients had gynecologic and
urologic surgery, respectively. Details on the characteristics
of interventions are specified in Table 1. In the majority of
cases, primary tumor was the target (77.4%) and radicality
(ablation of cancer lesion(s) and of regional nodes, if the
case), the intention (78.9%) of surgery.
Endoscopic surgery was performed in 21.2% of pa-
tients, most of them in urology (61% of this specific setting).
Duration of anesthesia was longer than 2 hours in 76.3% of
patients, mainly in general surgery, while urology presented
a significant proportion of interventions lasting less than 45
minutes (32.0%).
Tumor staging was determined by means of TNM or
FIGO classifications in 92.9% of patients. These patients
were reviewed by experts in the specific surgical field to
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categorize the case as “advanced” or “not advanced”: 45.9%
and 47.0% of patients were classified as affected with “not-
advanced” or “advanced” disease, respectively. The more
frequent known sites of primary tumor (frequency  50
cases) are listed in Table 2.
The mean duration ( SD) of the postoperative hospital
stay was 12.3 ( 8.7), 9.1 ( 6.9), and 6.2 ( 5.6) days after
general, gynecologic, and urologic surgery, respectively. Bed
rest following intervention was shorter than 4 days in the
majority of patients (84.4%), with no significant differences
among the 3 types of surgery. Postoperative chemotherapy
and/or radiotherapy were reported in 21.5% of the patients.
Antithrombotic Prophylaxis
In-hospital antithrombotic prophylaxis was given in
81.7% of patients (general surgery, 86.8%; gynecology,
82.7%; urology, 71.7%), while postdischarge prophylaxis
was used in 30.7% of the patients (general surgery, 30.1%;
gynecology, 29.5%; urology, 32.5%). A prophylaxis lasting
more than 21 days was used in 553 patients (23.3%).
Low molecular weight heparin (LMWH) was used in
approximately three fourths of the treated patients, both for
in-hospital and postdischarge prophylaxis (74.3% and 77.2%
of cases, respectively). Specifically, LMWH prophylaxis was
started before surgery in 71.1% of the cases. Physical meth-
ods, mainly as combination therapy, were used in 10.4% and
5.5% of patients undergoing prophylaxis during hospital stay
or following discharge, respectively. Other pharmacologic
methods of prophylaxis were unfractionated heparin (18.7%
and 3.9% of patients with in-hospital or postdischarge pro-
phylaxis) and heparinoids (2.6%, in-hospital). Antiplatelets
and oral anticoagulants, 10.9% and 3.9%, respectively, were
given postdischarge in patients that had temporarily inter-
rupted these agents before surgery.
Venous Thromboembolic Events
A total of 2360 (99.5%) patients were followed up as
stated by study protocol. A total of 92 patients with suspected
thromboembolic events or deaths were reported during the
study and reviewed by the external independent Adjudication
Committee.
Fifty of these patients (2.1%) were adjudicated as
affected by VTE or as dead due to PE (Fig. 1A). Isolated
DVT was confirmed in 10 (0.40%) patients, nonfatal PE in 21
(0.88%) patients (in 16 cases isolated PE, in 5 associated with
DVT). Death was attributed to VTE in 19 cases (0.82%). The
incidence of VTE was 2.8% in general surgery, 2.0% in
gynecologic surgery, and 0.87% in urologic surgery (Fig.
1B). Regarding thromboembolic events, the clinical interpre-
tation of the local investigators and the Adjudication Com-
mittee was consistent in 85% of cases. In the 8 patients with
an inconsistent interpretation, the Adjudication Committee
called VTE 6 cases not locally diagnosed as DVT or PE,
while 2 episodes locally adjudicated as VTE were not con-
firmed by the external Committee.
For primary tumor sites present in more than 50 pa-
tients, the rate of patients with VTE is shown in Figure 2. The
rate of thromboembolic events in patients with gastroenteric
tract, lung, or kidney cancer was higher than the overall
incidence rate. No patients with primary hepatic tumor expe-
rienced VTE; however, in 5 patients with VTE, an interven-
tion involving liver (for secondary lesions) had been done.
Table 3 shows the distribution of patients with and
without VTE according to selected covariates and the results
TABLE 2. Site of Primary Tumor
Site of Primary Tumor No. (%)
Urinary bladder 447 (18.8)
Colon 362 (15.3)
Rectum 209 (8.8)
Uterus 201 (8.4)
Stomach 179 (7.5)
Prostate 140 (5.9)
Ovary 139 (5.9)
Kidney 79 (3.3)
Liver 71 (3.0)
Pancreas 64 (2.7)
Lung 57 (2.4)
TABLE 1. Characteristics of Surgery
Characteristic No. (%) of Patients
Site(s) of surgery
Primary tumor 1836 (77.4)
Multiple primary tumors 32 (1.3)
Primary tumor(s)  metastases 272 (11.4)
Metastases 233 (9.8)
Type of surgery
Radical 1872 (78.9)
Not radical 338 (14.2)
Palliative 163 (6.9)
Endoscopic surgery
Total 504 (21.2)
General surgery 32 (2.6)*
Gynecology 54 (12.0)*
Urology 418 (61.0)*
Type of anesthesia
General 2121 (89.4)
Local 252 (10.6)
Duration of anesthesia
Total  45 min 227 (9.6)
0.45 min–1.59 hr 336 (14.1)
2.00 hr 1810 (76.3)
General surgery  45 min 2 (0.2)
0.45 min–1.59 hr 102 (8.2)
2.00 hr 1134 (91.6)
Gynecology  45 min 6 (1.3)
0.45 min–1.59 hr 87 (19.3)
2.00 hr 357 (79.4)
Urology  45 min 219 (32.0)
0.45 min–1.59 hr 147 (21.4)
2.00 hr 319 (46.6)
*Percentage within each surgical setting.
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of a multivariable logistic regression analysis performed with
the aim to identify potential risk factors for VTE. The risk of
VTE increased with age: in comparison with patients under
60 years, the OR of VTE was 2.6 (95% CI, 1.2–5.7) in those
over 60 years. Likewise, a previous history of VTE (OR, 6.0;
95% CI, 2.1–16.8), a prolonged duration of surgical proce-
dure (anesthesia lasting over 2 hours versus less than 2 hours;
OR, 4.5; 95% CI, 1.1–19.0), a prolonged bed stay after
surgery (more than or equal to 4 days versus less than 4 days;
OR, 2.7; 95% CI, 1.4–5.2), and an advanced tumor (OR, 4.4;
95% CI, 2.5–7.8) all appeared to enhance the risk of VTE.
Venous thromboembolic events occurred during pro-
phylaxis in the majority of cases (37, corresponding to 74%).
In 12 VTE patients (24%), prophylaxis had been discontinued
(1–23 days) before the occurrence of the event; in the remaining
patient, antithrombotic prophylaxis was not used at all.
An additional multivariable logistic regression analysis
was performed to evaluate the factors which influence the
surgeon’s decision to use or not antithrombotic prophylaxis.
Some factors were significantly associated with the use of
prophylaxis: age 60 years or older versus under 60 years (OR,
1.5; 95% CI, 1.2–1.9), general versus local anesthesia (OR,
2.3; 1.6–3.3), scheduled duration of anesthesia longer than or
equal to 2 hours versus less than 2 hours (OR, 3.7; 2.8–5.0),
advanced versus not advanced staging of the disease (OR,
1.5; 1.1–1.9), combined surgery of primary tumor and
metastasis versus intervention on primary tumor alone
(OR, 2.4; 1.3–4.2). Prophylaxis was used less frequently
when surgery was performed for secondary lesions in
comparison to primary tumors (OR, 0.6; 0.4 –0.8). There
TABLE 3. Prognostic Risk Factors for VTE: Multivariable
Logistic Regression Analysis
Variable Effect
No. of Patients
VTE/Non-VTE OR 95% CI
Age class 60 versus
60 yr
60 yr: 42/1.516
60 yr: 8/807
2.6 1.2–5.7
Previous VTE Yes versus no Yes: 5/36 6.0 2.1–16.8
No: 45/2.287
Anesthesia 2:00 versus
2:00 hr
2:00 hr: 48/1.762
2:00 hr: 2/561
4.5 1.1–19.0
Staging Advanced versus
not advanced
Advanced:
38/1.078
2.7 1.4–5.2
Not advanced:
12/1.245
Bed rest 4 versus
4 days
4 days: 25/346 4.4 2.5–7.8
4 days: 25/1.977
FIGURE 1. A, Venous thromboembolic events confirmed or
not by the Adjudication Committee. B, Distribution of con-
firmed events by surgery.
FIGURE 2. Incidence of VTE in reference to site of primary
tumor.
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was no significant difference in the physician’s decision
regarding nonendoscopic versus endoscopic surgery (OR,
0.9; 0.7–1.4).
Time distribution of venous thromboembolic events is
shown in Figure 3. Mean ( SD) time of occurrence of
thromboembolic events was 17.2  14.0 days (range, 2–58
days). Forty percent of the events (20 cases) were observed
more than 21 days from surgery; in 9 of these patients (45%),
the event occurred after prophylaxis was withdrawn. The risk
factors listed in Table 3 were analyzed separately for early
(ie, within 15 days from surgery) or late VTE: no difference
in the OR estimates emerged (data not shown).
Bleeding
Bleeding episodes were recorded in 9.9% of patients. In
half of the bleeding episodes (5.0%), blood transfusion was
not required. When transfusions were necessary, surgeons
were asked to classify the episodes as “expected” or “unex-
pected” according to the type of surgery and the patient’s
condition. In the majority of cases (69.7%), bleeding was
considered “expected.” The incidence of unexpected bleeding
requiring transfusion was 1.5%. In 3 of 4 patients who died
due to bleeding, prophylaxis had been discontinued when
bleedings occurred.
Bleeding occurred more frequently in patients who
received antithrombotic prophylaxis in comparison to pa-
tients not treated (11.4% versus 3.0%, P  0.001). By means
of a multivariable logistic regression analysis, we found that
antithrombotic prophylaxis was given more frequently in
patients aged more than 60 years, in the case of surgery
lasting more than 2 hours, and in patients with advanced
disease.
Mortality
Forty-one patients died during the scheduled observa-
tion period (overall death rate, 1.72%). Death rates in the
specific surgical settings were 2.91% for general surgery,
0.22% for gynecology surgery, and 0.58% for urology. Ve-
nous thromboembolism was adjudicated as the most common
cause of death (19 of 41 cases, 46.3%). The other causes of
death were disease progression (5 cases), liver failure (3
cases), bleeding (3 cases), stroke (2 cases), sepsis (2 cases),
and cardiac arrest, acute myocardial infarction, disseminated
intravascular coagulation, pancreatitis, respiratory failure, re-
nal failure, and multiorgan failure (1 case each). In the 4
bleeding-related deaths, pharmacologic antithrombotic pro-
phylaxis was ongoing at the time of the event in 1 patient, it
had been previously discontinued (16 and 33 days before) in
2, while it had not been used at all in the remaining one
(hemorrhagic stroke).
DISCUSSION
In recent years, cancer surgery has undergone a number
of changes; hence, the need for up-to-date data on the epide-
miology of VTE in this clinical setting. This study shows that
the incidence of venous thromboembolic events after cancer
surgery is not negligible. The risk of VTE persists after the
conventional period of antithrombotic prophylaxis. Risk fac-
tors, seen in previous venography trials, have been confirmed
in this clinical outcome-based study.
The clinical relevance of asymptomatic venography-
detected DVT has been challenged over the years.7 This
study, focused on clinically overt venous thromboembolic
events, confirms the clinical importance of postoperative
VTE after cancer surgery. It is noteworthy that most of the
events were PE and death. The relatively low incidence of
DVT is potentially explained by the intrinsic nature of post-
operative DVT: nonocclusive and therefore often asymptom-
atic. Our study seems to indicate that nonocclusive asymp-
tomatic DVT leads to PE. A potential, although partial,
impact of asymptomatic pelvic DVT in this context cannot be
excluded; in our study, 14 of 50 cases of total thromboem-
bolic events and 6 of 20 cases with isolated symptomatic PE
occurred in patients undergoing pelvic surgery.
In recent years, prolonged prophylaxis has been pro-
posed in cancer surgery on the base of a venography study.8
Our study confirms previous findings on the persistence of
risk of VTE after the perioperative period, showing that 40%
of VTE events occurred more than 21 days from surgery.
Interestingly, antithrombotic prophylaxis was extended be-
yond 3 weeks after surgery in only 23% of patients, and
almost half of the VTE events occurring later than 21 days
took place after withdrawal of prophylaxis.
In this study, age, previous VTE, advanced disease,
duration of surgery, and bed rest are confirmed as risk factors
for VTE. These features or some of these may explain the
difference in the incidence observed between the individual
types of surgery. Indeed, the incidence of VTE events in
general surgery was 3 times higher than in urology surgery.
General surgery, in comparison to urology, was characterized
by a higher proportion of interventions of prolonged duration,
and patients more frequently had advanced disease (69%
versus 12%).
Our study was not designed to address the issue of
bleeding complications after cancer surgery as well as to
evaluate the benefit to risk ratio of antithrombotic prophylaxis
in this clinical setting. However, we observed a high overall
bleeding rate as well as a higher bleeding rate in patients
FIGURE 3. Time distribution of venous thromboembolic
events.
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receiving prophylaxis in comparison to those not receiving
prophylaxis.
The overall high bleeding rate observed in our study
could be explained by the fact that surgeons were asked to
report all bleeding events regardless of whether they were
clinically major or minor. Of interest, about 50% of the
reported bleeding events did not require blood transfusions as
they were probably minor bleedings. In addition, the high
bleeding rate observed in our study could be explained by the
intrinsic differences between the study populations of regis-
tries and clinical trials. Patients included in clinical trials are
usually selected by strict criteria and this often results in the
exclusion of patients at high bleeding risk.
The higher bleeding rate seen in patients receiving
prophylaxis in comparison to those not receiving prophylaxis
could have several explanations. Reporting of intraoperative
or postoperative bleedings was mainly based on clinical
perception; therefore, the open design of our study may have
led to an overestimation of the bleeding complications in
patients receiving antithrombotic prophylaxis, as it was ob-
served previously.9 Antithrombotic prophylaxis was given
more frequently in patients aged more than 60 years, in the
case of surgery lasting more than 2 hours, and in patients with
advanced disease. Therefore, prophylaxis was probably given
to patients at high risk of bleeding. However, the rate of
unexpected bleeding requiring transfusion was as low as
1.5%. Based on all these considerations, it is conceivable to
believe that the increased bleeding rate seen in our registry do
not challenge the documented favorable benefit to risk ratio
of antithrombotic prophylaxis in cancer surgery.
Our registry, like other observational studies, has cer-
tainly some intrinsic limitations. Among these, the absence of
standardization in the prophylaxis regimens. Nevertheless, it
should be mentioned that, consistent with the current guide-
lines, most of the patients received LMWH prophylaxis.
However, our study has some methodologic strengths
that may make our results valid. We included consecutive
patients undergoing a wide spectrum of cancer surgery.
Patients were closely followed up as scheduled by study
protocol in 99% of the cases. All suspected clinical events
were prospectively collected and validated by an external
independent Adjudication Committee using predefined stan-
dard criteria. Further, death accounted for a large proportion
of the outcome events. As quality assurance of recorded data,
the study included active monitoring in each study center to
verify the consistency between source documents and data
reported on electronic case report forms. Moreover, elec-
tronic data capture allowed a central, real-time check of
recorded data.
CONCLUSION
The results of our study have potential implications for
clinical practice and future research. The persistently high
incidence of VTE after cancer surgery, despite improvements
in patient care, requires a high level of attention even now-
adays. The incidence of VTE events remains high despite
prophylaxis, hence requiring further improvement, particu-
larly in patients with known risk factors. The high proportion
of late occurring events suggests the need of extending
antithrombotic prophylaxis beyond hospital discharge and/or
the conventional perioperative period.
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